US20030069253A1 - Compositions and methods for treating otic, ophthalmic and nasal infections - Google Patents

Compositions and methods for treating otic, ophthalmic and nasal infections Download PDF

Info

Publication number
US20030069253A1
US20030069253A1 US10/253,335 US25333502A US2003069253A1 US 20030069253 A1 US20030069253 A1 US 20030069253A1 US 25333502 A US25333502 A US 25333502A US 2003069253 A1 US2003069253 A1 US 2003069253A1
Authority
US
United States
Prior art keywords
microbacterium
compositions
ophthalmic
composition according
otic
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
US10/253,335
Inventor
Gerald Cagle
Robert Abshire
David Stroman
Celeste McLean
Linda Clark
John Yanni
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Alcon Inc
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Priority to US10/253,335 priority Critical patent/US20030069253A1/en
Publication of US20030069253A1 publication Critical patent/US20030069253A1/en
Assigned to ALCON, INC. reassignment ALCON, INC. ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: ALCON MANUFACTURING, LTD.
Abandoned legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5383—1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/74—Synthetic polymeric materials
    • A61K31/765—Polymers containing oxygen
    • A61K31/77—Polymers containing oxygen of oxiranes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0043—Nose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A61P31/06—Antibacterial agents for tuberculosis

Definitions

  • the present invention is directed to the provision of topical pharmaceutical compositions for treating otic infections, particularly acute otitis externa infections caused by two newly discovered bacterial species, Microbacterium sp. nov. otitidis and Microbacterium sp. nov. alconae.
  • the present inventors have isolated these species, and have determined that these species are pathogens in acute otitis externa infections.
  • the present invention is directed to the provision of topical pharmaceutical compositions and methods for treating otic infections that are partially or wholly attributable to these newly discovered bacterial species, as well as ophthalmic and nasal infections wherein these species are acting as pathogens.
  • the compositions and methods of the present invention are based on the use of quinolone antibiotics to treat such infections, particularly second and third generation quinolones, such as gatifloxacin and moxifloxacin, respectively.
  • Quinolone antibiotics have been previously utilized to treat ophthalmic and otic infections.
  • a topical ophthalmic composition containing the quinolone ciprofloxacin is marketed by Alcon Laboratories, Inc. under the name CILOXANTM (Ciprofloxacin 0.3%) Ophthalmic Solution
  • a topical otic composition containing a combination of ciprofloxacin and hydrocortisone is marketed by Alcon Laboratories, Inc. under the name CIPROTM HC.
  • quinolones have also been utilized in ophthalmic antibiotic compositions: Quinolone Product Manufacturer Ofloxacin OCUFLOX TM Allergan Norfloxacin CHIBROXIN TM Merck Lomefloxacin LOMEFLOX TM Senju
  • quinolone antibiotic compositions are generally effective in treating ophthalmic infections, and have distinct advantages over prior ophthalmic antibiotic compositions, particularly those having relatively limited spectrums of antimicrobial activity, such as: neomycin, polymyxin B, gentamicin and tobramycin, which are primarily useful against gram negative pathogens; and bacitracin, gramicidin, and erythromycin, which are primarily active against gram positive pathogens.
  • Ophthalmic, otic and nasal infections are frequently accompanied by inflammation of the infected ophthalmic, otic and nasal tissues and perhaps even surrounding tissues.
  • ophthalmic, otic and nasal surgical procedures that create a risk of microbial infections frequently also cause inflammation of the affected tissues.
  • ophthalmic, otic and nasal pharmaceutical compositions that combine the anti-infective activity of one or more antibiotics with the anti-inflammatory activity of one or more steroid or non-steroid agents in a single composition.
  • the invention is based on the use of a potent new class of antibiotics to treat ophthalmic, otic and nasal infections, as well as the use of these antibiotics prior to surgery to sterilize the surgical field and prophylactically following surgery or other trauma to otic, ophthalmic or nasal tissues to minimize the risk of infection.
  • the compositions of the present invention may also be administered to the affected tissues during otic, ophthalmic or nasal surgical procedures to prevent or alleviate post-surgical infection.
  • the terms “treat”, “treating” and derivations thereof are intended to include both treatments of existing infections and treatments to prevent or reduce the risk of infections.
  • compositions preferably also contain one or more anti-inflammatory agents to treat inflammation associated with infections of otic, ophthalmic, or nasal tissues.
  • the anti-inflammatory component of the compositions is also useful in treating inflammation associated with physical trauma to otic, ophthalmic, or nasal tissues, including inflammation resulting from surgical procedures.
  • the compositions of the present invention are therefore particularly useful in treating inflammation associated with trauma to otic, ophthalmic, or nasal tissues wherein there is either an infection or a risk of an infection resulting from the trauma.
  • compositions of the present invention examples include conjunctivitis, keratitis, blepharitis, dacyrocystitis, hordeolum and corneal ulcers.
  • the compositions of the invention may also be used prophylactically in connection with various ophthalmic surgical procedures that create a risk of infection.
  • Examples of otic conditions that may be treated with the compostions of the present invention include otitis externa and otitis media.
  • the compositions of the present invention are primarily useful in cases where the tympanic membrane has ruptured or tympanostomy tubes have been implanted.
  • the compositions may also be used to treat infections associated with otic surgical procedures, such as tympanostomy, or to prevent such infections.
  • compositions and methods of the present invention are particularly useful in the treatment of acute infections of the external ear canal, which are commonly referred to as “acute otitis externa” or “AOE”.
  • AOE acute otitis externa
  • the present invention is based in part on the isolation of two bacterial species that have not previously been identified as pathogens relative to acute otitis externa infections. These bacterial species are described in greater detail below.
  • the present invention is also based in part on a finding that the quinolone antibiotics utilized in the present invention, particularly third generation quinolones, such as Moxifloxacin, have a very high level of antimicrobial activity against these newly discovered pathogens, and therefore are particularly useful in the treatment of acute otitis externa infections involving these pathogens.
  • compositions of the present invention are specially formulated for topical application to otic, ophthalmic, and nasal tissues.
  • the compositions are preferably sterile, and have physical properties (e.g., osmolality and pH) that are specially suited for application to otic, ophthalmic, and nasal tissues, including tissues that have been compromised as the result of preexisting disease, trauma, surgery or other physical conditions.
  • the antibiotics used in the compositions and methods of the present invention classified as quinolones.
  • the preferred quinolones are second generation quinolones, such as Gatifloxacin, and third generation quinolones, such as Moxifloxacin.
  • second generation quinolones such as Gatifloxacin
  • third generation quinolones such as Moxifloxacin.
  • the designation of quinolone antibiotics as “second generation” or “third generation” is well known in the field of antibiotic therapy. This knowledge is reflected in numerous scientific articles, such as: Blondeau, J. M., “A review of the comparative in-vitro activities of 12 antimicrobial agents, with a focus on five new ‘respiratory quinolones’”, J. of Antimicrobial Chemotherapy, 43, Suppl. B. 1-11 (1999); Tillotson, G.
  • the preferred quinolone antibiotics are second generation quinolones, such as Ciprofloxacin, Ofloxacin, Gatifloxacin and Grepafloxacin, and third generation quinolones, such as Moxifloxacin and Trovafloxacin.
  • second generation quinolones such as Ciprofloxacin, Ofloxacin, Gatifloxacin and Grepafloxacin
  • third generation quinolones such as Moxifloxacin and Trovafloxacin.
  • Examples of second and third generation quinolones that may be utilized in the present invention are provided below.
  • A is CH, CF, CCl, C—OCH 3 , or N;
  • X 1 is H, halogen, NH 2 , or CH 3 ;
  • R 1 is C 1 to C 3 alkyl, FCH 2 CH 2 , cyclopropyl or phenyl, optionally mono-, di- or tri-substituted by halogen, or A and R 1 together can form a bridge of formula C—O—CH 2 —CH(CH 3 );
  • R 2 is H, C 1 to C 3 alkyl (optionally substituted by OH, halogen or NH 2 ), or 5-methyl-2-oxo-1,3-dioxol-4-yl-methyl;
  • B is a selected from the group consisting of:
  • Y is O or CH 2 ;
  • R 3 is C 2 -C 5 alkoxyl, CH 2 —CO—C 6 H 5 , CH 2 CH 2 CO 2 R′, R′O 2 C—CH ⁇ C—CO 2 R′, CH ⁇ CH—CO 2 R′ or CH 2 CH 2 —CN,
  • R′ is H or C 1 to C 3 alkyl
  • R 4 is H, C 1 to C 3 alkyl, C 2 -C 5 alkoxyl, CH 2 —CO—C 6 H 5 , CH 2 CH 2 CO 2 R′, R′O 2 C—CH ⁇ C—CO 2 R′, CH ⁇ CH—CO 2 R′, CH 2 CH 2 —CN or 5-methyl-2-oxo-1,3-dioxol-4-yl-methyl,
  • R′ is H or C 1 to C 3 alkyl
  • Moxifloxacin has the following structure:
  • R1 is hydrogen, a pharmaceutically acceptable cation, or (C1-C6) alkyl
  • Y when taken independently, is ethyl, t-butyl, vinyl, cyclopropyl, 2-fluoroethyl, p-fluorophenyl, or o,p-difluorophenyl;
  • W is hydrogen, F, Cl, Br, C1-C4 alkyl, C1-C4 alkoxy, NH2 or NHCH3;
  • A is CH, CF, CCl, COCH3, C—CH3, C—CN or N;
  • A is carbon and is taken together with Y and the carbon and nitrogen to which A and Y are attached to form a five or six membered ring which may contain oxygen or a double bond, and which may have attached thereto R8 which is methyl or methylene;
  • R3, R4, R5, R6, R7, R9, R10 and R25 are each independently H, CH3, CH2NH2, CH2NHCH3 or CH2NHC2H5, and R5, R6, R7, and R9 may also independently be NH2, NHCH3 or NHC2H5, provided that not more than three of R3, R4, R5, R6, R7, R9, R10 and R25 are other than hydrogen, and if three of these substituents are not hydrogen, at least one of them is methyl.
  • the antibiotics utilized in the present invention also include prodrugs of the compounds of formula (II) having a free amino group, as well as pharmaceutically useful hydrates and salts of the compounds of formula (II).
  • Trovafloxacin has the following structure:
  • the second generation quinolones that may be utilized in the present invention include Gatifloxacin and related compounds of the following formula:
  • R indicates a hydrogen atom or lower alkyl group
  • R1 indicates a lower alkyl group
  • R2 indicates a hydrogen atom
  • X indicates a halogen atom
  • Z indicates a halogen atom, piperazino group, N-methylpiperazino group, 3-methylpiperazino group, 3-hydroxypyrrolidino group, or pyrrolidino group of the following formula
  • n is 0 or 1
  • R3 indicates a lower alkylgroup
  • R4 indicates a hydrogen atom, lower alkyl group, hydroxy-substituted lower alkyl group or halogenated lower alkyl group
  • R5 indicates a hydrogen atom, lower alkyl group, acyl group or alkoxycarbonyl group, the hydrates or the pharmaceutically acceptable acid addition or alklai salts thereof.
  • Gatifloxacin has the following structure:
  • the second generation quinolones that may be utilized in the present invention also include Ciprofloxacin, Ofloxacin and Levofloxacin, as well as Grepafloxacin and related compounds of the following formula:
  • R1 is a cyclopropyl which may be substituted by 1 to 3 of substituents selected from the group consisting of a C 1 -C 6 alkyl and a halogen atom, a phenyl which may be substituted by 1 to 3 of substituents selected from the group consisting of C 1 -C 6 alkoxy, a halogen atom and hydroxy, a C 1 -C 6 alkyl which may be substituted by a halogen atom, a C 2 -C 6 alkanoyloxy or hydroxy, a C 2 -C 6 alkenyl or thienyl;
  • R2 is a member selected from the group consisting of a 1-piperazinyl group which may have 1 to 3 substituents selected from the group consisting of a C 1 -C 6 alkyl group, a C 1 -C 6 alkanoyl group, a phenyl (C 1 -C 6 ) alkyl group, and a 2-oxo-1,3-dioxolenemethyl group which may be substituted by a phenyl group or a C 1 -C 6 alkyl group; a 1-pyrrolidinyl group which may have 1 to 3 substituents selected from the group consisting of an amino group which can have 1 or 2 substituents selected from a C 1 -C 6 alkyl group and a (C 1 -C 6 )alkooxy-carbonyl group, an amino(C 1 -C 6 )alkyl group which may have 1 to 2 substituents selected from C 1 -C 6 alkyl group and a (C 1 -C 6 )
  • R3 is a C 1 -C 6 alkyl
  • R is hydrogen atom or a C 1 -C 6 alkyl
  • X is a halogen atom, or a pharmaceutically acceptable salt thereof.
  • the compound Grepafloxacin has the following structure:
  • the concentrations of the antibiotics of formula (I) in the compositions of the present invention will vary depending on the intended use of the compositions (e.g., treatment of existing infections or prevention of post-surgical infections), and the relative antimicrobial activity of the specific antibiotic selected.
  • the antimicrobial activity of antibiotics is generally expressed as the minimum concentration required to inhibit the growth of a specified pathogen. This concentration is also referred to as the “minimum inhibitory concentration” or “MIC”.
  • MIC 90 refers to the minimum concentration of antibiotic required to inhibit the growth of ninety percent (90%) of the strains of a species.
  • the concentration of an antibiotic required to totally kill a specified bacteria is referred to as the “minimum bactericidal concentration” or “MBC”.
  • the minimum inhibitory concentrations of Moxifloxacin, Trovafloxacin, Gatifloxacin and Grepafloxacin, relative to several bacteria commonly associated with otic, ophthalmic, and nasal infections, are provided in the following tables, wherein the concentrations are expressed as micrograms per milliliter: Microorganism MIC 90 Moxifloxacin S. aureus /methicillin sensitive 0.13 S. aureus /methicillin resistant 4.0 S. aureus /quinolone resistant 4.0 S. epidermidis /methicillin sensitive 0.25 S. epidermidis /methicillin resistant 4.0 S. pneumoniae /penicillin sensitive 0.25 S. pneumoniae /penicillin resistant 0.25 P. aeruginosa 8.0 H.
  • the present invention is based in part on the identification of two bacterial species that are believed to act as pathogens in acute otitis externa infections. These bacteria belong to the class known as “coryneforms” or “diphtheroids”. Bacteria belonging to this class have been previously identified as being present both in healthy ears and in ears afflicted with acute otitis externa infections. However, prior to the present invention, there had been no species-level identification of the coryneform bacteria present either in healthy ears or infected ears, nor had there been any attempt to eradicate the pathogenic species present in acute otitis externa infections with antibiotic therapy keyed to those species.
  • the present inventors have now identified two species of coryneform bacteria as being present in acute otitis externa infections, and have determined that quinolone antibiotics, particularly third generation quinolones such as Moxifloxacin, are very effective in eradicating these species.
  • the bacterial species referred to above were identified as a result of research conducted on specimens obtained from 2,122 ears afflicted with acute otitis externa infections and 82 healthy ears. Coryneform bacteria of some type were isolated from 10 to 30% of these ears overall; the incidence of finding this class of bacteria present varied depending on the season when the specimen was taken. Although coryneform bacteria have been identified previously in both healthy and infected ears, the present inventors have discovered that the coryneform bacteria present in healthy ears and in acute otitis externa ears are different. In the acute otitis externa ears, 80% of the coryneform bacteria identified belong to the genus Microbacterium, while in the healthy ears, 90% of the coryneform bacteria identified belong to the genus Turicella.
  • the present inventors have also discovered that the coryneform bacteria found in acute otitis externa patients include two species that have not previously been identified. These species are now identified as Microbacterium sp. nov. otitidis and Microbacterium sp. nov. alconae. These names for the species have been assigned by the inventors, but have not yet been officially published. The names utilized for these species below are “ Microbacterium otitidis ” (sometimes abbreviated as “ M. otitidis ”) and “ Microbacterium alconae ” (sometimes abbreviated as “ M. alconae ”), respectively.
  • M. otitidis and M. alconae isolates were identified as being present, these species were the only type of bacteria recovered. Moreover, these species were not recovered from healthy ears.
  • M. otitidis and M. alconae are pathogens in acute otitis externa. That is, these species were either largely or totally responsible for the acute otitis externa infections in the ears from which they were isolated.
  • the above-cited findings are believed to represent the first frequent association of the genus Microbacterium with a human infectious disease, namely, acute otitis externa.
  • the two new Microbacterium species that have been discovered to be pathogens in acute otitis externa are described in greater detail below.
  • M. otitidis is most closely related to M. hominis
  • M. alconae is most closely related to M. maritypicum and M. liquefaciens.
  • Both species of Microbacterium grow optimally at 28-30° C.
  • the M. otitidis isolates grow up to 37° C.
  • the M. alconae isolates grow up to 35° C.
  • the optimal growth temperature at 28-30° C. is typical for bacteria that are normally found in water and soil.
  • M. otitidis isolates are most easily distinguished from M. hominis by their inability to metabolize: 1) N-acetyl-D-glucosamine, 2) 3-methyl glucose, 3) alaninamide, or 4) L-serine.
  • the isolates of M. alconae can be distinguished from M. liquefaciens by their ability to metabolize: 1) amygdalin, 2) D-mannitol, 3) D-melezitose, 4) palatinose, 5) D-psicose, 6) salicin, 7) D-sorbitol, 8) D-xylose, or 9) p-hydoxyphenyl acetic acid.
  • M. alconae can be distinguished from M. maritypicum by their ability to metabolize: 1) amygdalin or 2) D-xylose, and can be distinguished from M. maritypicum by their inability to metabolize: 1) L-fucose.
  • the appropriate antibiotic concentration for ophthalmic compositions will generally be an amount of one or more antibiotics of formula (I) sufficient to provide a concentration in the aqueous humor and lacrimal fluid of the eye equal to or greater than the MIC 90 level for the selected antibiotic(s), relative to gram-negative and gram-positive organisms commonly associated with ophthalmic infections.
  • the appropriate concentration for otic and nasal compositions will generally be an amount of one or more antibiotics of formula (I) sufficient to provide a concentration in the infected tissues equal to or greater than the MIC 90 level for the selected antibiotic(s), relative to gram-negative and gram-positive organisms commonly associated with otic or nasal infections. Such amounts are referred to herein as “an antimicrobial effective amount”.
  • the compositions of the present invention will typically contain one or more compounds of formula (I) in a concentration of from about 0.1 to about 1.0 percent by weight (“wt. %”) of the compositions.
  • compositions of the present invention may also contain one or more anti-inflammatory agents.
  • the anti-inflammatory agents utilized in the present invention are broadly classified as steroidal or non-steroidal.
  • the preferred steroidal anti-inflammatory agents are glucocorticoids.
  • the preferred glucocorticoids for ophthalmic and otic use include dexamethasone, loteprednol, rimexolone, prednisolone, fluorometholone, and hydrocortisone.
  • the preferred glucocorticoids for nasal use include mometasone, fluticasone, beclomethasone, flunisolide, triamcinolone and budesonide.
  • dexamethasone derivatives described in U.S. Pat. No. 5,223,493 are also preferred steroidal anti-inflammatory agents, particularly with respect to compositions for treating ophthalmic inflammation.
  • the following compounds are especially preferred:
  • 21-ether derivatives of dexamethasone are referred to herein as “21-ether derivatives of dexamethasone”.
  • the 21 -benzyl ether derivative i.e., compound AL-2512 is particularly preferred.
  • the preferred non-steroidal anti-inflammatory agents are: prostaglandin H synthetase inhibitors (Cox I or Cox II), also referred to as cyclooxygenase type I and type II inhibitors, such as diclofenac, flurbiprofen, ketorolac, suprofen, nepafenac, amfenac, indomethacin, naproxen, ibuprofen, bromfenac, ketoprofen, meclofenamate, piroxicam, sulindac, mefanamic acid, diflusinal, oxaprozin, tolmetin, fenoprofen, benoxaprofen, nabumetome, etodolac, phenylbutazone, aspirin, oxyphenbutazone, NCX-4016, HCT-1026, NCX-284, NCX-456, tenoxicam and carprofen; cyclooxygenase type
  • compositions of the present invention will vary based on the agent or agents selected and the type of inflammation being treated. The concentrations will be sufficient to reduce inflammation in the targeted ophthalmic, otic or nasal tissues following topical application of the compositions to those tissues. Such an amount is referred to herein as “an anti-inflammatory effective amount”.
  • the compositions of the present invention will typically contain one or more anti-inflammatory agents in an amount of from about 0.01 to about 1.0 wt. %.
  • compositions are typically administered to the affected ophthalmic, otic or nasal tissues by topically applying one to four drops of a sterile solution or suspension, or a comparable amount of an ointment, gel or other solid or semisolid composition, one to four times per day.
  • the compositions may also be formulated as irrigating solutions that are applied to the affected ophthalmic, otic or nasal tissues during surgical procedures.
  • the ophthalmic, otic and nasal compositions of the present invention will contain one or more compounds of formula (I) and preferably one or more anti-inflammatory agents, in pharmaceutically acceptable vehicles.
  • the compositions will typically have a pH in the range of 4.5 to 8.0.
  • the ophthalmic compositions must also be formulated to have osmotic values that are compatible with the aqueous humor of the eye and ophthalmic tissues. Such osmotic values will generally be in the range of from about 200 to about 400 milliosmoles per kilogram of water (“mOsm/kg”), but will preferably be about 300 mOsm/kg.
  • Ophthalmic, otic and nasal pharmaceutical products are typically packaged in multidose form. Preservatives are thus required to prevent microbial contamination during use. Suitable preservatives include: polyquaternium-1, benzalkonium chloride, thimerosal, chlorobutanol, methyl paraben, propyl paraben, phenylethyl alcohol, edetate disodium, sorbic acid, or other agents known to those skilled in the art. The use of polyquaternium-1 as the antimicrobial preservative is preferred. Typically such preservatives are employed at a level of from 0.001% to 1.0% by weight.
  • the solubility of the components of the present compositions may be enhanced by a surfactant or other appropriate co-solvent in the composition.
  • co-solvents include polysorbate 20, 60, and 80, polyoxyethylene/polyoxypropylene surfactants (e.g., Pluronic F-68, F-84 and P-103), cyclodextrin, or other agents known to those skilled in the art.
  • co-solvents are employed at a level of from 0.01% to 2% by weight.
  • viscosity enhancing agents to provide the compositions of the invention with viscosities greater than the viscosity of simple aqueous solutions may be desirable to increase ocular absorption of the active compounds by the target tissues or increase the retention time in the eye, ear or nose.
  • viscosity building agents include, for example, polyvinyl alcohol, polyvinyl pyrrolidone, methyl cellulose, hydroxy propyl methylcellulose, hydroxyethyl cellulose, carboxymethyl cellulose, hydroxy propyl cellulose or other agents know to those skilled in the art. Such agents are typically employed at a level of from 0.01% to 2% by weight.
  • MCC Computed Cell Culture Collection
  • MCC 10647 represent separate clinical isolates of the two Microbacterium species tested.
  • the figures set forth in the table are the minimum inhibitory concentrations for each compound, relative to the respective isolates of the two Microbacterium species, expressed as micrograms per milliliter.

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Otolaryngology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pulmonology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)

Abstract

Ophthalmic, otic and nasal compositions containing a new class of antibiotics (e.g., moxifloxacin) are disclosed. The compositions preferably also contain one or more anti-inflammatory agents. The compositions may be utilized to treat ophthalmic, otic and nasal conditions by topically applying the compositions to the affected tissues. The compositions and methods of the invention are particularly useful in the treatment of acute otitis externa infections attributable to one or both of two newly identified Microbacterium species, Microbacterium otitidis and Microbacterium alconae.

Description

    CLAIM FOR PRIORITY
  • The present application is a continuation of U.S. patent application Ser. No. 09/575,850 filed May 19, 2000, which claims priority from International Application Serial Nos. PCT/US99/22622; PCT/US99/22624; and PCT/US99/22625 filed Sep. 29, 1999, which claim priority from U.S. Provisional Application Serial Nos. 60/102,504; 60/102,506; 60/102,508; 60/102,509; 60/102,510 and 60/102,511 filed Sep. 30, 1998.[0001]
    • BACKGROUND OF THE INVENTION
  • The present invention is directed to the provision of topical pharmaceutical compositions for treating otic infections, particularly acute otitis externa infections caused by two newly discovered bacterial species, Microbacterium sp. nov. otitidis and Microbacterium sp. nov. alconae. The present inventors have isolated these species, and have determined that these species are pathogens in acute otitis externa infections. The present invention is directed to the provision of topical pharmaceutical compositions and methods for treating otic infections that are partially or wholly attributable to these newly discovered bacterial species, as well as ophthalmic and nasal infections wherein these species are acting as pathogens. The compositions and methods of the present invention are based on the use of quinolone antibiotics to treat such infections, particularly second and third generation quinolones, such as gatifloxacin and moxifloxacin, respectively. [0002]
  • Quinolone antibiotics have been previously utilized to treat ophthalmic and otic infections. For example, a topical ophthalmic composition containing the quinolone ciprofloxacin is marketed by Alcon Laboratories, Inc. under the name CILOXAN™ (Ciprofloxacin 0.3%) Ophthalmic Solution, and a topical otic composition containing a combination of ciprofloxacin and hydrocortisone is marketed by Alcon Laboratories, Inc. under the name CIPRO™ HC. The following quinolones have also been utilized in ophthalmic antibiotic compositions: [0003]
    Quinolone Product Manufacturer
    Ofloxacin OCUFLOX ™ Allergan
    Norfloxacin CHIBROXIN ™ Merck
    Lomefloxacin LOMEFLOX ™ Senju
  • The foregoing quinolone antibiotic compositions are generally effective in treating ophthalmic infections, and have distinct advantages over prior ophthalmic antibiotic compositions, particularly those having relatively limited spectrums of antimicrobial activity, such as: neomycin, polymyxin B, gentamicin and tobramycin, which are primarily useful against gram negative pathogens; and bacitracin, gramicidin, and erythromycin, which are primarily active against gram positive pathogens. However, despite the general efficacy of the ophthalmic quinolone therapies currently available, there is a need for improved compositions and methods of treatment based on the use of antibiotics that are more effective than existing antibiotics against key ophthalmic pathogens, and less prone to the development of resistance by those pathogens. [0004]
  • There is an even greater need for effective topical compositions and methods for treating otic and nasal infections, particularly bacterial infections. The use of oral antibiotics to treat otic infections in children has limited efficacy, and creates a serious risk of pathogen resistance to the orally administered antibiotics. Although ciprofloxacin has proven to be an effective agent in treating otic infections, there is a need for a better understanding of the etiology of these infections and a corresponding need for therapies that address the causes of these infections more directly and effectively. [0005]
  • Ophthalmic, otic and nasal infections are frequently accompanied by inflammation of the infected ophthalmic, otic and nasal tissues and perhaps even surrounding tissues. Similarly, ophthalmic, otic and nasal surgical procedures that create a risk of microbial infections frequently also cause inflammation of the affected tissues. Thus, there is also a need for ophthalmic, otic and nasal pharmaceutical compositions that combine the anti-infective activity of one or more antibiotics with the anti-inflammatory activity of one or more steroid or non-steroid agents in a single composition. [0006]
    • SUMMARY OF THE INVENTION
  • The invention is based on the use of a potent new class of antibiotics to treat ophthalmic, otic and nasal infections, as well as the use of these antibiotics prior to surgery to sterilize the surgical field and prophylactically following surgery or other trauma to otic, ophthalmic or nasal tissues to minimize the risk of infection. The compositions of the present invention may also be administered to the affected tissues during otic, ophthalmic or nasal surgical procedures to prevent or alleviate post-surgical infection. As utilized herein, the terms “treat”, “treating” and derivations thereof are intended to include both treatments of existing infections and treatments to prevent or reduce the risk of infections. [0007]
  • The compositions preferably also contain one or more anti-inflammatory agents to treat inflammation associated with infections of otic, ophthalmic, or nasal tissues. The anti-inflammatory component of the compositions is also useful in treating inflammation associated with physical trauma to otic, ophthalmic, or nasal tissues, including inflammation resulting from surgical procedures. The compositions of the present invention are therefore particularly useful in treating inflammation associated with trauma to otic, ophthalmic, or nasal tissues wherein there is either an infection or a risk of an infection resulting from the trauma. [0008]
  • Examples of ophthalmic conditions that may be treated with the compositions of the present invention include conjunctivitis, keratitis, blepharitis, dacyrocystitis, hordeolum and corneal ulcers. The compositions of the invention may also be used prophylactically in connection with various ophthalmic surgical procedures that create a risk of infection. [0009]
  • Examples of otic conditions that may be treated with the compostions of the present invention include otitis externa and otitis media. With respect to the treatment of otitis media, the compositions of the present invention are primarily useful in cases where the tympanic membrane has ruptured or tympanostomy tubes have been implanted. The compositions may also be used to treat infections associated with otic surgical procedures, such as tympanostomy, or to prevent such infections. [0010]
  • The compositions and methods of the present invention are particularly useful in the treatment of acute infections of the external ear canal, which are commonly referred to as “acute otitis externa” or “AOE”. The present invention is based in part on the isolation of two bacterial species that have not previously been identified as pathogens relative to acute otitis externa infections. These bacterial species are described in greater detail below. The present invention is also based in part on a finding that the quinolone antibiotics utilized in the present invention, particularly third generation quinolones, such as Moxifloxacin, have a very high level of antimicrobial activity against these newly discovered pathogens, and therefore are particularly useful in the treatment of acute otitis externa infections involving these pathogens. [0011]
  • The compositions of the present invention are specially formulated for topical application to otic, ophthalmic, and nasal tissues. The compositions are preferably sterile, and have physical properties (e.g., osmolality and pH) that are specially suited for application to otic, ophthalmic, and nasal tissues, including tissues that have been compromised as the result of preexisting disease, trauma, surgery or other physical conditions. [0012]
    • BRIEF DESCRIPTION OF THE DRAWING
  • The sole figure of drawings is an automated ribotyping chart showing the relationships between two newly identified bacterial species and other, known species.[0013]
    • DETAILED DESCRIPTION OF THE INVENTION
  • The antibiotics used in the compositions and methods of the present invention classified as quinolones. The preferred quinolones are second generation quinolones, such as Gatifloxacin, and third generation quinolones, such as Moxifloxacin. The designation of quinolone antibiotics as “second generation” or “third generation” is well known in the field of antibiotic therapy. This knowledge is reflected in numerous scientific articles, such as: Blondeau, J. M., “A review of the comparative in-vitro activities of 12 antimicrobial agents, with a focus on five new ‘respiratory quinolones’”, [0014] J. of Antimicrobial Chemotherapy, 43, Suppl. B. 1-11 (1999); Tillotson, G. S., “Quinolones: structure-activity relationships and future predictions”, J. of Medical Microbiology, 44, 320-4 (1996); Wentland, M. P., “Structure-activity relationships of fluoroquinolones”, In the New Generation of Quinolones, (Siporin, C., Heifetz, C. L. & Domagala, J. M., Eds), pp. 1-43, Marcel Dekker, New York (1990); and Gootz, T. D. and Brighty, K. E., “Fluoroquinolone antibacterials: SAR mechanism of action, resistance, and clinical aspects”, Medicinal Research Reviews 16, 433-86 (1996). These articles provide further details regarding the structure/activity relationships of quinolone antibiotics and the classification of quinolones as second generation or third generation.
  • The preferred quinolone antibiotics are second generation quinolones, such as Ciprofloxacin, Ofloxacin, Gatifloxacin and Grepafloxacin, and third generation quinolones, such as Moxifloxacin and Trovafloxacin. The third generation quinolones are most preferred. Examples of second and third generation quinolones that may be utilized in the present invention are provided below. [0015]
  • The most preferred third generation quinolones are Moxifloxacin and related compounds of the following formula: [0016]
    Figure US20030069253A1-20030410-C00001
  • wherein: [0017]
  • A is CH, CF, CCl, C—OCH[0018] 3, or N;
  • X[0019] 1 is H, halogen, NH2, or CH3;
  • R[0020] 1 is C1 to C3 alkyl, FCH2CH2, cyclopropyl or phenyl, optionally mono-, di- or tri-substituted by halogen, or A and R1 together can form a bridge of formula C—O—CH2—CH(CH3);
  • R[0021] 2 is H, C1 to C3 alkyl (optionally substituted by OH, halogen or NH2), or 5-methyl-2-oxo-1,3-dioxol-4-yl-methyl; and
  • B is a selected from the group consisting of: [0022]
    Figure US20030069253A1-20030410-C00002
  • wherein: [0023]
  • Y is O or CH[0024] 2;
  • R[0025] 3 is C2-C5 alkoxyl, CH2—CO—C6H5, CH2CH2CO2R′, R′O2C—CH═C—CO2R′, CH═CH—CO2R′ or CH2CH2—CN,
  • wherein: [0026]
  • R′ is H or C[0027] 1 to C3 alkyl;
  • R[0028] 4 is H, C1 to C3 alkyl, C2-C5 alkoxyl, CH2—CO—C6H5, CH2CH2CO2R′, R′O2C—CH═C—CO2R′, CH═CH—CO2R′, CH2CH2—CN or 5-methyl-2-oxo-1,3-dioxol-4-yl-methyl,
  • wherein: [0029]
  • R′ is H or C[0030] 1 to C3 alkyl; and
  • their pharmaceutically useful hydrates and salts. [0031]
  • The compound Moxifloxacin is most preferred. Moxifloxacin has the following structure: [0032]
    Figure US20030069253A1-20030410-C00003
  • Further details regarding the structure, preparation, and physical properties of Moxifloxacin and other compounds of formula (I) are provided in U.S. Pat. No. 5,607,942. The contents of U.S. Pat. No. 5,607,942 relating to the structure, physical properties, and preparation of the compounds of formula (I) are hereby incorporated in the present specification by reference. [0033]
  • Other third generation quinolones that may be utilized in the present invention include Trovafloxacin and related compounds of the following formula: [0034]
    Figure US20030069253A1-20030410-C00004
  • wherein [0035]
  • R1 is hydrogen, a pharmaceutically acceptable cation, or (C1-C6) alkyl; [0036]
  • Y, when taken independently, is ethyl, t-butyl, vinyl, cyclopropyl, 2-fluoroethyl, p-fluorophenyl, or o,p-difluorophenyl; [0037]
  • W is hydrogen, F, Cl, Br, C1-C4 alkyl, C1-C4 alkoxy, NH2 or NHCH3; [0038]
  • A is CH, CF, CCl, COCH3, C—CH3, C—CN or N; or [0039]
  • A is carbon and is taken together with Y and the carbon and nitrogen to which A and Y are attached to form a five or six membered ring which may contain oxygen or a double bond, and which may have attached thereto R8 which is methyl or methylene; [0040]
  • and [0041]
  • R2 is [0042]
    Figure US20030069253A1-20030410-C00005
  • wherein: [0043]
  • R3, R4, R5, R6, R7, R9, R10 and R25 are each independently H, CH3, CH2NH2, CH2NHCH3 or CH2NHC2H5, and R5, R6, R7, and R9 may also independently be NH2, NHCH3 or NHC2H5, provided that not more than three of R3, R4, R5, R6, R7, R9, R10 and R25 are other than hydrogen, and if three of these substituents are not hydrogen, at least one of them is methyl. [0044]
  • The antibiotics utilized in the present invention also include prodrugs of the compounds of formula (II) having a free amino group, as well as pharmaceutically useful hydrates and salts of the compounds of formula (II). [0045]
  • The compound Trovafloxacin is most preferred. Trovafloxacin has the following structure: [0046]
    Figure US20030069253A1-20030410-C00006
  • Further details regarding the structure, preparation, and physical properties of Trovafloxacin and other compounds of formula (II) are provided in U.S. Pat. No. 5,164,402. The contents of U.S. Pat. No. 5,164,402 relating to the structure, physical properties, and preparation of the compounds of formula (II) are hereby incorporated in the present specification by reference. [0047]
  • The second generation quinolones that may be utilized in the present invention include Gatifloxacin and related compounds of the following formula: [0048]
    Figure US20030069253A1-20030410-C00007
  • wherein R indicates a hydrogen atom or lower alkyl group, R1 indicates a lower alkyl group, R2 indicates a hydrogen atom X indicates a halogen atom, and Z indicates a halogen atom, piperazino group, N-methylpiperazino group, 3-methylpiperazino group, 3-hydroxypyrrolidino group, or pyrrolidino group of the following formula, [0049]
    Figure US20030069253A1-20030410-C00008
  • where, n is 0 or 1, R3 indicates a lower alkylgroup, R4 indicates a hydrogen atom, lower alkyl group, hydroxy-substituted lower alkyl group or halogenated lower alkyl group and R5 indicates a hydrogen atom, lower alkyl group, acyl group or alkoxycarbonyl group, the hydrates or the pharmaceutically acceptable acid addition or alklai salts thereof. [0050]
  • The compound Gatifloxacin is most preferred. Gatifloxacin has the following structure: [0051]
    Figure US20030069253A1-20030410-C00009
  • Further details regarding the structure, preparation, and physical properties of Gatifloxacin and other compounds of formula (III) are provided in U.S. Pat. No. 4,980,470. The contents of U.S. Pat. No. 4,980,470 relating to the structure, physical properties, and preparation of the compounds of formula (III) are hereby incorporated in the present specification by reference. [0052]
  • The second generation quinolones that may be utilized in the present invention also include Ciprofloxacin, Ofloxacin and Levofloxacin, as well as Grepafloxacin and related compounds of the following formula: [0053]
    Figure US20030069253A1-20030410-C00010
  • wherein [0054]
  • R1 is a cyclopropyl which may be substituted by 1 to 3 of substituents selected from the group consisting of a C[0055] 1-C6 alkyl and a halogen atom, a phenyl which may be substituted by 1 to 3 of substituents selected from the group consisting of C1-C6 alkoxy, a halogen atom and hydroxy, a C1-C6 alkyl which may be substituted by a halogen atom, a C2-C6 alkanoyloxy or hydroxy, a C2-C6 alkenyl or thienyl;
  • R2 is a member selected from the group consisting of a 1-piperazinyl group which may have 1 to 3 substituents selected from the group consisting of a C[0056] 1-C6 alkyl group, a C1-C6 alkanoyl group, a phenyl (C1-C6) alkyl group, and a 2-oxo-1,3-dioxolenemethyl group which may be substituted by a phenyl group or a C1-C6 alkyl group; a 1-pyrrolidinyl group which may have 1 to 3 substituents selected from the group consisting of an amino group which can have 1 or 2 substituents selected from a C1-C6 alkyl group and a (C1-C6)alkooxy-carbonyl group, an amino(C1-C6)alkyl group which may have 1 to 2 substituents selected from C1-C6 alkyl group and a (C1-C6)alkoxy-carbonyl group on the amino moiety, and a C1-C6 alkyl group; a morpholino group which may have 1 to 3 substituents of C1-C6 alkyl groups; a 1-piperidinyl group which may have 1 to 3 substituents selected from the group consisting of a C1-C6 alkyl group, hydroxy, a halogen atom and oxo group; and a 1,4-diazobicyclo[4.3.0]nonan-4-yl group;
  • R3 is a C[0057] 1-C6 alkyl;
  • R is hydrogen atom or a C[0058] 1-C6 alkyl; and
  • X is a halogen atom, or a pharmaceutically acceptable salt thereof. [0059]
  • The compound Grepafloxacin has the following structure: [0060]
    Figure US20030069253A1-20030410-C00011
  • Further details regarding the structure, preparation, and physical properties of Grepafloxacin and other compounds of formula (IV) are provided in U.S. Pat. No. 5,563,138. The contents of U.S. Pat. No. 5,563,138 relating to the structure, physical properties, and preparation of the compounds of formula (IV) are hereby incorporated in the present specification by reference. [0061]
  • The concentrations of the antibiotics of formula (I) in the compositions of the present invention will vary depending on the intended use of the compositions (e.g., treatment of existing infections or prevention of post-surgical infections), and the relative antimicrobial activity of the specific antibiotic selected. The antimicrobial activity of antibiotics is generally expressed as the minimum concentration required to inhibit the growth of a specified pathogen. This concentration is also referred to as the “minimum inhibitory concentration” or “MIC”. The term “MIC[0062] 90” refers to the minimum concentration of antibiotic required to inhibit the growth of ninety percent (90%) of the strains of a species. The concentration of an antibiotic required to totally kill a specified bacteria is referred to as the “minimum bactericidal concentration” or “MBC”. The minimum inhibitory concentrations of Moxifloxacin, Trovafloxacin, Gatifloxacin and Grepafloxacin, relative to several bacteria commonly associated with otic, ophthalmic, and nasal infections, are provided in the following tables, wherein the concentrations are expressed as micrograms per milliliter:
    Microorganism MIC90
    Moxifloxacin
    S. aureus/methicillin sensitive 0.13
    S. aureus/methicillin resistant 4.0
    S. aureus/quinolone resistant 4.0
    S. epidermidis/methicillin sensitive 0.25
    S. epidermidis/methicillin resistant 4.0
    S. pneumoniae/penicillin sensitive 0.25
    S. pneumoniae/penicillin resistant 0.25
    P. aeruginosa 8.0
    H. influenzae/β-lactamase positive 0.06
    H influenzae/β-lactamase negative 0.06
    M. otitidis 2.0
    M. alconae 0.25
    Trovafloxacin
    S. aureus/methicillin sensitive 0.03
    S. aureus/methicillin resistant 2.0
    S. aureus/quinolone resistant 4.0
    S. epidermidis/methicillin sensitive 0.06
    S. epidermidis/methicillin resistant 4.0
    S. pneumoniae/penicillin sensitive 0.25
    S. pneumoniae/penicillin resistant 0.25
    P. aeruginosa 2.0
    H. influenzae/β-lactamase positive 0.03
    H influenzae/β-lactamase negative 0.03
    Gatifloxacin
    S. aureus/methicillin sensitive 0.25
    S. aureus/methicillin resistant 8.0
    S. aureus/quinolone resistant 8.0
    S. epidermidis/methicillin sensitive 0.50
    S. epidermidis/methicillin resistant 4.0
    S. pneumoniae/penicillin sensitive 0.25
    S. pneumoniae/penicillin resistant 0.25
    P. aeruginosa 2.0
    H. influenzae/β-lactamase positive 0.06
    H influenzae/β-lactamase negative 0.06
    Grepafloxacin
    S. aureus/methicillin sensitive 0.13
    S. aureus/methicillin resistant 0.13
    S. aureus/quinolone resistant 0.13
    S. epidermidis/methicillin sensitive 0.13
    S. epidermidis/methicillin resistant 0.13
    S. pneumoniae/penicillin sensitive 0.25
    S. pneumoniae/penicillin resistant 0.25
    P. aeruginosa 8.0
    H. influenzae/β-lactamase positive 0.008
    H influenzae/β-lactamase negative 0.008
  • As indicated above, the present invention is based in part on the identification of two bacterial species that are believed to act as pathogens in acute otitis externa infections. These bacteria belong to the class known as “coryneforms” or “diphtheroids”. Bacteria belonging to this class have been previously identified as being present both in healthy ears and in ears afflicted with acute otitis externa infections. However, prior to the present invention, there had been no species-level identification of the coryneform bacteria present either in healthy ears or infected ears, nor had there been any attempt to eradicate the pathogenic species present in acute otitis externa infections with antibiotic therapy keyed to those species. The present inventors have now identified two species of coryneform bacteria as being present in acute otitis externa infections, and have determined that quinolone antibiotics, particularly third generation quinolones such as Moxifloxacin, are very effective in eradicating these species. [0063]
  • The bacterial species referred to above were identified as a result of research conducted on specimens obtained from 2,122 ears afflicted with acute otitis externa infections and 82 healthy ears. Coryneform bacteria of some type were isolated from 10 to 30% of these ears overall; the incidence of finding this class of bacteria present varied depending on the season when the specimen was taken. Although coryneform bacteria have been identified previously in both healthy and infected ears, the present inventors have discovered that the coryneform bacteria present in healthy ears and in acute otitis externa ears are different. In the acute otitis externa ears, 80% of the coryneform bacteria identified belong to the genus Microbacterium, while in the healthy ears, 90% of the coryneform bacteria identified belong to the genus Turicella. [0064]
  • The present inventors have also discovered that the coryneform bacteria found in acute otitis externa patients include two species that have not previously been identified. These species are now identified as Microbacterium sp. nov. otitidis and Microbacterium sp. nov. alconae. These names for the species have been assigned by the inventors, but have not yet been officially published. The names utilized for these species below are “[0065] Microbacterium otitidis” (sometimes abbreviated as “M. otitidis”) and “Microbacterium alconae” (sometimes abbreviated as “M. alconae”), respectively.
  • In two thirds of the cases where [0066] M. otitidis or M. alconae isolates were identified as being present, these species were the only type of bacteria recovered. Moreover, these species were not recovered from healthy ears. These findings lead to the conclusion that M. otitidis and M. alconae are pathogens in acute otitis externa. That is, these species were either largely or totally responsible for the acute otitis externa infections in the ears from which they were isolated. The above-cited findings are believed to represent the first frequent association of the genus Microbacterium with a human infectious disease, namely, acute otitis externa. The two new Microbacterium species that have been discovered to be pathogens in acute otitis externa are described in greater detail below.
  • Both new species can be distinguished from the 27 recognized species of Microbacterium phenotypically and genetypically. Genetypically, [0067] M. otitidis is most closely related to M. hominis, while M. alconae is most closely related to M. maritypicum and M. liquefaciens.
  • The two new Microbacterium species have been characterized for taxomonic purposes using DNA methods as well as phenotypic methods. The sequencing of the 16S rRNA gene showed that both sets of strains belonged to the genus Microbacterium, although the sequence differences from established Microbacterium species were significant enough to suggest novel species. Automated ribotyping patterns further clarified the relationships (similarities and differences) with known Microbacterium species. These relationships are shown in FIG. 1. The above-cited analyses support the categorization of these bacteria as new species. [0068]
  • Both species of Microbacterium grow optimally at 28-30° C. The [0069] M. otitidis isolates grow up to 37° C., while the M. alconae isolates grow up to 35° C. The optimal growth temperature at 28-30° C. is typical for bacteria that are normally found in water and soil.
  • Phenotypically, the [0070] M. otitidis isolates are most easily distinguished from M. hominis by their inability to metabolize: 1) N-acetyl-D-glucosamine, 2) 3-methyl glucose, 3) alaninamide, or 4) L-serine. The isolates of M. alconae can be distinguished from M. liquefaciens by their ability to metabolize: 1) amygdalin, 2) D-mannitol, 3) D-melezitose, 4) palatinose, 5) D-psicose, 6) salicin, 7) D-sorbitol, 8) D-xylose, or 9) p-hydoxyphenyl acetic acid. Also, M. alconae can be distinguished from M. maritypicum by their ability to metabolize: 1) amygdalin or 2) D-xylose, and can be distinguished from M. maritypicum by their inability to metabolize: 1) L-fucose.
  • Analysis of cellular fatty acids for the [0071] M. otitidis isolates showed the three major fatty acids to be: 1) 17:0 anteiso—60%, 2) 15:0 anteiso—26%, and 3) 16:0 iso—11%. Analysis of the M. alconae isolates showed the three major fatty acids to be: 1) 15:0 anteiso—55%, 2) 17:0 anteiso—23%, and 3) 16:0 iso—11%.
  • The appropriate antibiotic concentration for ophthalmic compositions will generally be an amount of one or more antibiotics of formula (I) sufficient to provide a concentration in the aqueous humor and lacrimal fluid of the eye equal to or greater than the MIC[0072] 90 level for the selected antibiotic(s), relative to gram-negative and gram-positive organisms commonly associated with ophthalmic infections. The appropriate concentration for otic and nasal compositions will generally be an amount of one or more antibiotics of formula (I) sufficient to provide a concentration in the infected tissues equal to or greater than the MIC90 level for the selected antibiotic(s), relative to gram-negative and gram-positive organisms commonly associated with otic or nasal infections. Such amounts are referred to herein as “an antimicrobial effective amount”. The compositions of the present invention will typically contain one or more compounds of formula (I) in a concentration of from about 0.1 to about 1.0 percent by weight (“wt. %”) of the compositions.
  • The compositions of the present invention may also contain one or more anti-inflammatory agents. The anti-inflammatory agents utilized in the present invention are broadly classified as steroidal or non-steroidal. The preferred steroidal anti-inflammatory agents are glucocorticoids. [0073]
  • The preferred glucocorticoids for ophthalmic and otic use include dexamethasone, loteprednol, rimexolone, prednisolone, fluorometholone, and hydrocortisone. The preferred glucocorticoids for nasal use include mometasone, fluticasone, beclomethasone, flunisolide, triamcinolone and budesonide. [0074]
  • The dexamethasone derivatives described in U.S. Pat. No. 5,223,493 (Boltralik) are also preferred steroidal anti-inflammatory agents, particularly with respect to compositions for treating ophthalmic inflammation. The following compounds are especially preferred: [0075]
    Figure US20030069253A1-20030410-C00012
  • These compounds are referred to herein as “21-ether derivatives of dexamethasone”. The 21 -benzyl ether derivative (i.e., compound AL-2512) is particularly preferred. [0076]
  • The preferred non-steroidal anti-inflammatory agents are: prostaglandin H synthetase inhibitors (Cox I or Cox II), also referred to as cyclooxygenase type I and type II inhibitors, such as diclofenac, flurbiprofen, ketorolac, suprofen, nepafenac, amfenac, indomethacin, naproxen, ibuprofen, bromfenac, ketoprofen, meclofenamate, piroxicam, sulindac, mefanamic acid, diflusinal, oxaprozin, tolmetin, fenoprofen, benoxaprofen, nabumetome, etodolac, phenylbutazone, aspirin, oxyphenbutazone, NCX-4016, HCT-1026, NCX-284, NCX-456, tenoxicam and carprofen; cyclooxygenase type II selective inhibitors, such as NS-398, vioxx, celecoxib, P54, etodolac, L-804600 and S-33516; PAF antagonists, such as SR-27417, A-137491, ABT-299, apafant, bepafant, minopafant, E-6123, BN-50727, nupafant and modipafant; PDE IV inhibitors, such as ariflo, torbafylline, rolipram, filaminast, piclamilast, cipamfylline, CG-1088, V-11294A, CT-2820, PD-168787, CP-293121, DWP-205297, CP-220629, SH-636, BAY-19-8004, and roflumilast; inhibitors of cytokine production, such as inhibitors of the NFkB transcription factor; or other anti-inflammatory agents known to those skilled in the art. [0077]
  • The concentrations of the anti-inflammatory agents contained in the compositions of the present invention will vary based on the agent or agents selected and the type of inflammation being treated. The concentrations will be sufficient to reduce inflammation in the targeted ophthalmic, otic or nasal tissues following topical application of the compositions to those tissues. Such an amount is referred to herein as “an anti-inflammatory effective amount”. The compositions of the present invention will typically contain one or more anti-inflammatory agents in an amount of from about 0.01 to about 1.0 wt. %. [0078]
  • The compositions are typically administered to the affected ophthalmic, otic or nasal tissues by topically applying one to four drops of a sterile solution or suspension, or a comparable amount of an ointment, gel or other solid or semisolid composition, one to four times per day. However, the compositions may also be formulated as irrigating solutions that are applied to the affected ophthalmic, otic or nasal tissues during surgical procedures. [0079]
  • The ophthalmic, otic and nasal compositions of the present invention will contain one or more compounds of formula (I) and preferably one or more anti-inflammatory agents, in pharmaceutically acceptable vehicles. The compositions will typically have a pH in the range of 4.5 to 8.0. The ophthalmic compositions must also be formulated to have osmotic values that are compatible with the aqueous humor of the eye and ophthalmic tissues. Such osmotic values will generally be in the range of from about 200 to about 400 milliosmoles per kilogram of water (“mOsm/kg”), but will preferably be about 300 mOsm/kg. [0080]
  • Ophthalmic, otic and nasal pharmaceutical products are typically packaged in multidose form. Preservatives are thus required to prevent microbial contamination during use. Suitable preservatives include: polyquaternium-1, benzalkonium chloride, thimerosal, chlorobutanol, methyl paraben, propyl paraben, phenylethyl alcohol, edetate disodium, sorbic acid, or other agents known to those skilled in the art. The use of polyquaternium-1 as the antimicrobial preservative is preferred. Typically such preservatives are employed at a level of from 0.001% to 1.0% by weight. [0081]
  • The solubility of the components of the present compositions may be enhanced by a surfactant or other appropriate co-solvent in the composition. Such co-solvents include polysorbate 20, 60, and 80, polyoxyethylene/polyoxypropylene surfactants (e.g., Pluronic F-68, F-84 and P-103), cyclodextrin, or other agents known to those skilled in the art. Typically such co-solvents are employed at a level of from 0.01% to 2% by weight. [0082]
  • The use of viscosity enhancing agents to provide the compositions of the invention with viscosities greater than the viscosity of simple aqueous solutions may be desirable to increase ocular absorption of the active compounds by the target tissues or increase the retention time in the eye, ear or nose. Such viscosity building agents include, for example, polyvinyl alcohol, polyvinyl pyrrolidone, methyl cellulose, hydroxy propyl methylcellulose, hydroxyethyl cellulose, carboxymethyl cellulose, hydroxy propyl cellulose or other agents know to those skilled in the art. Such agents are typically employed at a level of from 0.01% to 2% by weight. [0083]
  • The following examples are provided to further illustrate the ophthalmic, otic and nasal compositions of the present invention. [0084]
    • EXAMPLE 1 Ophthalmic/Otic/Nasal Solution
  • [0085]
    Ingredient Amount (wt. %)
    Moxifloxacin 0.35
    Sodium Acetate 0.03
    Acetic Acid 0.04
    Mannitol 4.60
    EDTA 0.05
    Benzalkonium Chloride 0.006
    Water q.s. 100
    • EXAMPLE 2 Ophthalmic/Otic/Nasal Suspension
  • [0086]
    Ingredient Amount (wt. %)
    Moxifloxacin 0.3
    Dexamethasone, Micronized USP 0.10
    Benzalkonium Chloride 0.01
    Edetate Disodium, USP 0.01
    Sodium Chloride, USP 0.3
    Sodium Sulfate, USP 1.2
    Tyloxapol, USP 0.05
    Hydroxyethylcellulose 0.25
    Sulfuric Acid and/or q.s. for pH adjustment to 5.5
    Sodium Hydroxide, NF
    Purified Water, USP q.s. to 100
    • EXAMPLE 3 Ophthalmic Ointment
  • [0087]
    Ingredient Amount (wt. %)
    Moxifloxacin 0.35
    Mineral Oil, USP 2.0
    White petrolatium, USP q.s 100
    • EXAMPLE 4 Ophthalmic Ointment
  • [0088]
    Ingredient Amount (wt. %)
    Moxifloxacin 0.3
    Fluorometholone Acetate, USP 0.1
    Chlorobutanol, Anhydrous, NF 0.5
    Mineral Oil,USP 5
    White Petrolatum, USP q.s. 100
  • The following example is provided to illustrate the activity of the compounds of formula (I) against the new Microbacterium species described above. [0089]
    • EXAMPLE 5
  • The in vitro activity of Moxifloxacin against [0090] Microbacterium otitidis and Microbacterium alconae was determined using conventional agar and broth dilution methods, such as those described in NCCLS Document M7-A4, entitled “Methods for Dilution Antimicrobial Susceptability Tests for Bacteria That Grow Aerobically” (4th Edition). The activity levels were determined as MIC (minimum inhibitory concentration) values. In order to compare the activity of the compounds of the present invention to other antibiotics, MIC values for representatives quinolones, aminoglycosides, β-lactams and other types of antibiotics were also determined. The results of these determinations are set forth in the table below:
    Activity of Moxifloxacin and Other Selected Antibiotics Against New Microbaterium Species
    Microbacterium otitidis Microbacterium alconae
    Isolate Number→ MCC MCC MCC MCC MCC MCC MCC MCC MCC MCC
    Antibiotic ↓ 10647 10810 10990 11495 11676 11316 11558 11639 11653 11699
    Quinolone
    Ciprofloxacin 32 32 32 32 32 1.0 1.0 1.0 2.0 2.0
    Moxifloxacin 2.0 2.0 2.0 2.0 2.0 0.25 0.25 0.25 0.25 0.25
    Ofloxacin 16 32 8.0 16 8.0 4.0 4.0 4.0 4.0 4.0
    Aminoglycosides
    Tobramycin 32 4.0 4.0 4.0 16 16 16 16 16 16
    Gentamicin 8.0 4.0 4.0 16 4.0 2.0 2.0 2.0 2.0 2.0
    Neomycin 8.0 2.0 2.0 8.0 2.0 1.0 1.0 1.0 1.0 1.0
    B-Lactams
    Oxacillin 2.0 4.0 2.0 4.0 2.0 8.0 16 32 32 32
    Other Antibiotics
    Erythromycin 0.03 0.03 0.03 0.03 0.03 1.0 2.0 2.0 0.50 0.50
    Clindamycin 0.03 0.03 0.03 0.03 0.03 4.0 4.0 4.0 4.0 4.0
    Tetracycline 1.0 1.0 1.0 1.0 1.0 1.0 1.0 1.0 1.0 1.0
    Chloramphenicol 1.0 1.0 1.0 1.0 1.0 16 16 16 16 16
    Polymyxin B 1040 260 260 1040 16 32.5 32.5 16 16 16
  • The letters “MCC” in the table above stand for “Microbiology Culture Collection”. The MCC numbers (e.g., “MCC 10647”) represent separate clinical isolates of the two Microbacterium species tested. The figures set forth in the table are the minimum inhibitory concentrations for each compound, relative to the respective isolates of the two Microbacterium species, expressed as micrograms per milliliter. [0091]
  • The invention has been described herein by reference to certain preferred embodiments. However, as obvious variations thereon will become apparent to those skilled in the art, the invention is not to be considered as limited thereto. [0092]

Claims (16)

What is claimed is:
1. A topical pharmaceutical composition for treating acute otitis externa infections attributable to a Microbacterium species selected from the group consisting of Microbacterium otitidis and Microbacterium alconae, comprising an antimicrobial effective amount of a quinolone antibiotic and a pharmaceutically acceptable vehicle therefor.
2. A composition according to claim 1, wherein the composition further comprises an effective amount of an antiinflammatory compound.
3. A composition according to claim 1, wherein the quinolone antibiotic comprises a third generation quinolone.
4. A composition according to claim 3, wherein the third generation quinolone comprises Moxifloxacin.
5. A composition according to claim 4, wherein the composition further comprises an effective amount of an antiinflammatory compound.
6. A composition according to claim 5, wherein the antiinflammatory compound comprises dexamethasone.
7. A composition according to claim 1, wherein the quinolone antibiotic comprises Gatifloxacin.
8. A method of treating acute otitis externa infections attributable to a Microbacterium species selected from the group consisting of Microbacterium otitidis and Microbacterium alconae, which comprises instilling a therapeutically effective amount of the composition of claim 1 in the affected ear.
9. A topical pharmaceutical composition for treating otic, ophthalmic or nasal infections attributable to a Microbacterium species selected from the group consisting of Microbacterium otitidis and Microbacterium alconae, comprising an antimicrobial effective amount of a quinolone antibiotic and a pharmaceutically acceptable vehicle therefor.
10. A composition according to claim 9, wherein the composition further comprises an effective amount of an antiinflammatory compound.
11. A composition according to claim 9, wherein the quinolone antibiotic comprises a third generation quinolone.
12. A composition according to claim 11, wherein the third generation quinolone comprises Moxifloxacin.
13. A composition according to claim 12, wherein the composition further comprises an effective amount of an antiinflammatory compound.
14. A composition according to claim 13, wherein the antiinflammatory compound comprises dexamethasone.
15. A composition according to claim 9, wherein the composition comprises Gatifloxacin.
16. A method of treating acute otitis externa infections attributable to a Microbacterium species selected from the group consisting of Microbacterium otitidis and Microbacterium alconae, which comprises instilling a therapeutically effective amount of the composition of claim 9 in the affected ear.
US10/253,335 2000-05-19 2002-09-24 Compositions and methods for treating otic, ophthalmic and nasal infections Abandoned US20030069253A1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
US10/253,335 US20030069253A1 (en) 2000-05-19 2002-09-24 Compositions and methods for treating otic, ophthalmic and nasal infections

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US09/575,850 US6509327B1 (en) 1998-09-30 2000-05-19 Compositions and methods for treating otic, ophthalmic and nasal infections
US10/253,335 US20030069253A1 (en) 2000-05-19 2002-09-24 Compositions and methods for treating otic, ophthalmic and nasal infections

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
US09/575,850 Continuation US6509327B1 (en) 1998-09-30 2000-05-19 Compositions and methods for treating otic, ophthalmic and nasal infections

Publications (1)

Publication Number Publication Date
US20030069253A1 true US20030069253A1 (en) 2003-04-10

Family

ID=24301946

Family Applications (2)

Application Number Title Priority Date Filing Date
US09/575,850 Expired - Lifetime US6509327B1 (en) 1998-09-30 2000-05-19 Compositions and methods for treating otic, ophthalmic and nasal infections
US10/253,335 Abandoned US20030069253A1 (en) 2000-05-19 2002-09-24 Compositions and methods for treating otic, ophthalmic and nasal infections

Family Applications Before (1)

Application Number Title Priority Date Filing Date
US09/575,850 Expired - Lifetime US6509327B1 (en) 1998-09-30 2000-05-19 Compositions and methods for treating otic, ophthalmic and nasal infections

Country Status (3)

Country Link
US (2) US6509327B1 (en)
AU (1) AU2001261752A1 (en)
WO (1) WO2001089496A2 (en)

Cited By (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060281779A1 (en) * 2003-09-10 2006-12-14 Kyorin Pharmaceutical Co., Ltd. 7-(4-Substituted-3-cyclopropylaminomethyl-1 pyrrolidinyl) quinolonecarboxylic acid derivative
US20070020298A1 (en) * 2003-12-31 2007-01-25 Pipkin James D Inhalant formulation containing sulfoalkyl ether gamma-cyclodextrin and corticosteroid
US20090029956A1 (en) * 2005-01-17 2009-01-29 Bruno Pregenzer Substance mixture
US20090312724A1 (en) * 2007-06-28 2009-12-17 Cydex Pharmaceuticals, Inc. Nasal and Ophthalmic Delivery of Aqueous Corticosteroid Solutions
US20100197909A1 (en) * 2007-05-24 2010-08-05 Yasumichi Fukuda Mutilin derivative having heterocyclic aromatic ring carboxylic acid structure in subtituent at 14-position
US20140162990A1 (en) * 2012-12-06 2014-06-12 Alcon Research, Ltd. Finafloxacin suspension compositions
US9827324B2 (en) 2003-12-31 2017-11-28 Cydex Pharmaceuticals, Inc. Inhalant formulation containing sulfoalkyl ether cyclodextrin and corticosteroid

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6716830B2 (en) * 1998-09-30 2004-04-06 Alcon, Inc. Ophthalmic antibiotic compositions containing moxifloxacin
JP4803935B2 (en) 1999-10-08 2011-10-26 アフィニアム・ファーマシューティカルズ・インコーポレイテッド FABI inhibitor
ATE420640T1 (en) * 2001-04-06 2009-01-15 Affinium Pharm Inc FAB I INHIBITORS
US7790709B2 (en) * 2002-12-06 2010-09-07 Affinium Pharmaceuticals, Inc. Heterocyclic compounds, methods of making them and their use in therapy
US7842791B2 (en) * 2002-12-19 2010-11-30 Nancy Jean Britten Dispersible pharmaceutical compositions
CA2519429C (en) 2003-03-17 2013-08-06 Affinium Pharmaceuticals, Inc. Pharmaceutical compositions comprising inhibitors of fab i and further antibiotics
US20050004098A1 (en) * 2003-03-20 2005-01-06 Britten Nancy Jean Dispersible formulation of an anti-inflammatory agent
US20040214753A1 (en) * 2003-03-20 2004-10-28 Britten Nancy Jean Dispersible pharmaceutical composition for treatment of mastitis and otic disorders
ES2270361T3 (en) * 2003-03-20 2007-04-01 Pharmacia Corporation DISPERSABLE FORMULATION OF AN ANTI-INFLAMMATOR AGENT.
US20050009931A1 (en) * 2003-03-20 2005-01-13 Britten Nancy Jean Dispersible pharmaceutical composition for treatment of mastitis and otic disorders
US20040202687A1 (en) * 2003-04-14 2004-10-14 Babu M.K. Manoj Ciprofloxacin formulations and methods of making and using the same
US20050085446A1 (en) * 2003-04-14 2005-04-21 Babu M.K. M. Fluoroquinolone formulations and methods of making and using the same
DK1828167T3 (en) 2004-06-04 2014-10-20 Debiopharm Int Sa Acrylamide derivatives as antibiotic agents
US7981104B2 (en) * 2005-01-25 2011-07-19 Patrick Slater Method for treating otitis externa
US8337481B2 (en) 2005-01-25 2012-12-25 Patrick Slater Method for treating otitis externa
US20090156578A1 (en) * 2005-12-05 2009-06-18 PAULS Henry 3-Heterocyclylacrylamide Compounds as Fab I Inhibitors and Antibacterial Agents
CA2658506C (en) 2006-07-20 2016-01-26 Affinium Pharmaceuticals, Inc. Acrylamide derivatives as fab 1 inhibitors
US8263613B2 (en) * 2007-02-16 2012-09-11 Affinium Pharmaceuticals, Inc. Salts, prodrugs and polymorphs of fab I inhibitors
BRPI0907511A2 (en) * 2008-02-15 2015-07-21 Alcon Res Ltd Topical ophthalmic pharmaceutical composition comprising fluoroquinolone derivatives for ophthalmic applications and use thereof
CN102026623B (en) * 2008-05-14 2013-08-14 奥德纳米有限公司 Controlled release corticosteroid compositions and methods for the treatment of otic disorders
US20100016450A1 (en) * 2008-07-21 2010-01-21 Otonomy, Inc. Controlled release delivery devices for the treatment of otic disorders
US8318817B2 (en) 2008-07-21 2012-11-27 Otonomy, Inc. Controlled release antimicrobial compositions and methods for the treatment of otic disorders
CN105687111A (en) 2009-07-02 2016-06-22 爱尔康研究有限公司 Compositions and methods for treating ophthalmic, otic, or nasal infections
EP2802209B1 (en) * 2012-01-10 2020-12-02 Entrx LLC Otic formulations
NZ702695A (en) 2012-06-19 2015-10-30 Debiopharm Int Sa Prodrug derivatives of (e)-n-methyl-n-((3-methylbenzofuran-2-yl)methyl)-3-(7-oxo-5,6,7,8-tetrahydro-1,8-naphthyridin-3-yl)acrylamide
US9849126B2 (en) 2013-01-03 2017-12-26 Entrx LLC Sterile otic formulations
CA2921816A1 (en) 2013-08-27 2015-03-05 Otonomy, Inc. Treatment of pediatric otic disorders
US11458041B2 (en) 2015-10-08 2022-10-04 Ocular Therapeutix, Inc. Punctal plug and bioadhesives
PT3419628T (en) 2016-02-26 2021-01-05 Debiopharm Int Sa Medicament for treatment of diabetic foot infections
WO2018053173A1 (en) 2016-09-16 2018-03-22 Otonomy, Inc. Otic gel formulations for treating otitis externa
AU2021215929A1 (en) 2020-02-06 2022-08-04 Ocular Therapeutix, Inc. Compositions and methods for treating ocular diseases
WO2021195163A1 (en) 2020-03-25 2021-09-30 Ocular Therapeutix, Inc. Ocular implant containing a tyrosine kinase inhibitor
BR112023004378A2 (en) 2020-09-24 2023-04-04 Ocular Therapeutix Inc BIODEGRADABLE SUSTAINED RELEASE INTRACANALICULAR INSERTS COMPRISING A HYDROGEL AND A CYCLOSPORIN

Family Cites Families (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4710495A (en) 1980-07-10 1987-12-01 Otsuka Pharmaceutical Co., Ltd. Soft steroids having anti-inflammatory activity
US4996335A (en) 1980-07-10 1991-02-26 Nicholas S. Bodor Soft steroids having anti-inflammatory activity
US4670444B1 (en) 1980-09-03 1999-02-09 Bayer Ag and-naphthyridine-3-carboxylic acids and antibacte7-amino-1-cyclopropyl-4-oxo-1,4-dihydro-quinoline-rial agents containing these compounds
US4730013A (en) 1981-10-08 1988-03-08 Merck & Co., Inc. Biosoluble ocular insert
US4474751A (en) 1983-05-16 1984-10-02 Merck & Co., Inc. Ophthalmic drug delivery system utilizing thermosetting gels
US4551456A (en) 1983-11-14 1985-11-05 Merck & Co., Inc. Ophthalmic use of norfloxacin and related antibiotics
US5223493A (en) 1984-12-28 1993-06-29 Alcon Laboratories, Inc. Anti-inflammatory compounds for ophthalmic use
JPH089597B2 (en) 1986-01-21 1996-01-31 杏林製薬株式会社 8-Alkoxyquinolonecarboxylic acid excellent in selective toxicity and its salt, and method for producing the same
DE3704907A1 (en) 1987-02-17 1988-08-25 Bayer Ag TOPICALLY APPLICABLE PREPARATIONS OF GYRASE INHIBITORS IN COMBINATION WITH CORTICOSTEROIDS
US5563138A (en) 1987-04-16 1996-10-08 Otsuka Pharmaceutical Company, Limited Benzoheterocyclic compounds
US4920120A (en) 1988-01-25 1990-04-24 Warner-Lambert Company Antibacterial agents
US5149694A (en) 1988-03-09 1992-09-22 Alcon Laboratories, Inc. Combination of tobramycin and dexamethasone for topical ophthalmic use
DE3906365A1 (en) 1988-07-15 1990-01-18 Bayer Ag 7- (1-PYRROLIDINYL) -3-CHINOLONE AND NAPHTHYRIDONE CARBOXYLIC ACID DERIVATIVES, METHOD AND SUBSTITUTED (OXA) DIAZABICYCLOOCTANES AND NONANESE AS INTERMEDIATE PRODUCTS, AND ANTIBACTERIAL AGENTS AND FOOD ADDITIVES CONTAINING THEM
AU4201189A (en) 1988-08-26 1990-03-23 Alcon Laboratories, Inc. Combination of quinolone antibiotics and steroids for topical ophthalmic use
US5360611A (en) 1988-10-03 1994-11-01 Alcon Laboratories, Inc. Pharmaceutical compositions and methods of treatment of the cornea following ultraviolet laser irradiation
US5185337A (en) 1989-03-29 1993-02-09 Otsuka Pharmaceutical Co., Ltd. Pyrroloquinoline derivatives and pharmaceutical compositions for antimicrobial use
US5164402A (en) 1989-08-16 1992-11-17 Pfizer Inc Azabicyclo quinolone and naphthyridinone carboxylic acids
TW209865B (en) 1992-01-10 1993-07-21 Bayer Ag
ES2079994B1 (en) * 1992-10-07 1996-08-01 Cusi Lab PHARMACEUTICAL FORMULATION BASED ON POLYMIXINE-TRIMETOPRIM AND AN ANTI-INFLAMMATORY AGENT FOR ITS TOPICAL OPHTHALMIC AND ETHICAL USE.
DE4234078A1 (en) 1992-10-09 1994-04-14 Bayer Ag Quinolonecarboxylic acids
US5631004A (en) 1993-09-30 1997-05-20 Alcon Laboratories, Inc. Use of sustained release antibiotic compositions in ophthalmic surgical procedures
US5540930A (en) 1993-10-25 1996-07-30 Pharmos Corporation Suspension of loteprednol etabonate for ear, eye, or nose treatment
ES2079320B1 (en) 1994-05-17 1996-10-16 Cusi Lab OPHTHALMIC DISSOLUTION BASED ON A DICLOFENACO AND TOBRAMYCIN AND ITS APPLICATIONS.
DE4424369A1 (en) 1994-07-11 1996-01-18 Bayer Ag Pyrido [3,2,1.i, j] [3,1] benzoxazine derivatives
PT782448E (en) 1995-06-06 2002-07-31 Bayer Ag NON-IRRITATING, NON-OTOTOXIC ANTIBACTERIAL OTIC FORMULATIONS
DE19546249A1 (en) 1995-12-12 1997-06-19 Bayer Ag New crystal modification of 1-cyclopropyl-7 - ([S, S] -2,8-diazabicyclo [4,3,0] non-8-yl) -6-fluoro-1,4-dihydro-8-methoxy-4 -oxo-3-quinoline carboxylic acid hydrochloride (CDCH), process for its preparation and pharmaceutical preparations containing it
AU4151697A (en) 1996-08-14 1998-03-06 Vanderbilt University Compositions of antichlamydial agents for the diagnosis and management of infection caused by (chlamydia)
PL192273B1 (en) 1997-09-25 2006-09-29 Bayer Ag Therapeutic agent preparation of controllable active substance release
US5912255A (en) 1998-02-27 1999-06-15 Bussell; Letantia Topical fluoroquinolone antibiotics combined with benzoyl peroxide
GB9818258D0 (en) 1998-08-21 1998-10-14 Pfizer Ltd Antifungal compositions
JP5138128B2 (en) 1998-08-21 2013-02-06 千寿製薬株式会社 Aqueous liquid
JP2002525326A (en) 1998-09-30 2002-08-13 アルコン ラボラトリーズ，インコーポレイテッド Antibiotic composition for treatment of eyes, ears and nose
AR020660A1 (en) 1998-09-30 2002-05-22 Alcon Lab Inc ANTIBIOTIC COMPOSITIONS FOR THE TREATMENT OF EYES, EARS AND NOSE
AR020661A1 (en) 1998-09-30 2002-05-22 Alcon Lab Inc A PHARMACEUTICAL COMPOSITION TOPICA OFTALMICA, OTICA OR NASAL AND THE USE OF THE SAME FOR THE MANUFACTURE OF A MEDICINAL PRODUCT
US6395746B1 (en) 1998-09-30 2002-05-28 Alcon Manufacturing, Ltd. Methods of treating ophthalmic, otic and nasal infections and attendant inflammation
US6093417A (en) * 1999-01-11 2000-07-25 Advanced Medical Instruments Composition to treat ear disorders
DE19962470A1 (en) 1999-12-22 2001-07-12 Schulz Hans Herrmann Use of chemotherapy drugs
AU2001261748A1 (en) 2000-05-19 2001-12-03 Alcon Laboratories Inc. Antibiotic compositions for treatment of the eye, ear and nose

Cited By (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8106072B2 (en) 2003-09-10 2012-01-31 Kyorin Pharmaceutical Co., Ltd. 7- (4-substituted-3-cyclopropylaminomethyl-1-pyrrolidinyl) quinolonecarboxylic acid derivative
US7514451B2 (en) 2003-09-10 2009-04-07 Kyorin Pharmaceutical Co., Ltd. 7-(4-Substituted-3-cyclopropylaminomethyl-1 pyrrolidinyl) quinolonecarboxylic acid derivative
US20060281779A1 (en) * 2003-09-10 2006-12-14 Kyorin Pharmaceutical Co., Ltd. 7-(4-Substituted-3-cyclopropylaminomethyl-1 pyrrolidinyl) quinolonecarboxylic acid derivative
US10159752B2 (en) 2003-12-31 2018-12-25 Cydex Pharmaceuticals, Inc. Inhalant formulation containing sulfoalkyl ether cyclodextrin and corticosteroid
US20070020298A1 (en) * 2003-12-31 2007-01-25 Pipkin James D Inhalant formulation containing sulfoalkyl ether gamma-cyclodextrin and corticosteroid
US9827324B2 (en) 2003-12-31 2017-11-28 Cydex Pharmaceuticals, Inc. Inhalant formulation containing sulfoalkyl ether cyclodextrin and corticosteroid
US10799599B2 (en) 2003-12-31 2020-10-13 Cydex Pharmaceuticals, Inc. Inhalant formulation containing sulfoalkyl ether cyclodextrin and corticosteroid
US10207008B2 (en) 2003-12-31 2019-02-19 Cydex Pharmaceuticals, Inc. Inhalant formulation containing sulfoalkyl ether cyclodextrin and corticosteroid
US20090029956A1 (en) * 2005-01-17 2009-01-29 Bruno Pregenzer Substance mixture
US8222407B2 (en) 2007-05-24 2012-07-17 Kyorin Pharmaceutical Co., Ltd. Mutilin derivative having heterocyclic aromatic ring carboxylic acid structure in substituent at 14-position
US20100197909A1 (en) * 2007-05-24 2010-08-05 Yasumichi Fukuda Mutilin derivative having heterocyclic aromatic ring carboxylic acid structure in subtituent at 14-position
US20090312724A1 (en) * 2007-06-28 2009-12-17 Cydex Pharmaceuticals, Inc. Nasal and Ophthalmic Delivery of Aqueous Corticosteroid Solutions
US20140162990A1 (en) * 2012-12-06 2014-06-12 Alcon Research, Ltd. Finafloxacin suspension compositions
US9504691B2 (en) * 2012-12-06 2016-11-29 Alcon Research, Ltd. Finafloxacin suspension compositions

Also Published As

Publication number Publication date
AU2001261752A1 (en) 2001-12-03
WO2001089496A3 (en) 2002-04-25
WO2001089496A2 (en) 2001-11-29
US6509327B1 (en) 2003-01-21

Similar Documents

Publication Publication Date Title
US6740664B2 (en) Methods for treating otic and ophthalmic infections
US6509327B1 (en) Compositions and methods for treating otic, ophthalmic and nasal infections
US6440964B1 (en) Compositions and methods for treating ophthalmic and otic infections
US8993636B2 (en) Compositions containing moxifloxacin for treating otic infections
US6395746B1 (en) Methods of treating ophthalmic, otic and nasal infections and attendant inflammation
CA2342211C (en) Antibiotic compositions for treatment of the eye, ear and nose
AU6275999A (en) Antibiotic compositions for treatment of the eye, ear and nose
WO2001089495A2 (en) Antibiotic compositions containing quinolone derivatives for treatment of the eye, ear and nose
AU2003248033B2 (en) Antibiotic Compositions for Treatment of the Eye, Ear and Nose
MXPA01003295A (en) Antibiotic compositions for treatment of the eye, ear and nose
MXPA01003293A (en) Antibiotic compositions for treatment of the eye, ear and nose
MXPA01003294A (en) Antibiotic compositions for treatment of the eye, ear and nose
AU2007201610A1 (en) Antibiotic compositions for treatment of the eye, ear and nose
ZA200101752B (en) Methods of treating or preventing ophthalmi infections with moxifloxacin.

Legal Events

Date Code Title Description
STCB Information on status: application discontinuation

Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION

AS Assignment

Owner name: ALCON, INC., SWITZERLAND

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:ALCON MANUFACTURING, LTD.;REEL/FRAME:014033/0537

Effective date: 20031009